{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:46:30Z","timestamp":1790419590918,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41375-021-01254-w","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T07:06:34Z","timestamp":1619593594000},"page":"1890-1893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?"],"prefix":"10.1038","volume":"35","author":[{"given":"Jerry L.","family":"Spivak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"1254_CR1","first-page":"85","volume":"2","author":"FP Weber","year":"1908","unstructured":"Weber FP. Polycythaemia, erythrocytosis and erythraemia. Q. J. Med.1908;2:85\u2013134.","journal-title":"Q. J. Med."},{"key":"1254_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jama.1950.02910290018005","volume":"142","author":"W Dameshek","year":"1950","unstructured":"Dameshek W. Physiopathology and course of polycythemia vera as related to therapy. JAMA. 1950;142:790\u20137.","journal-title":"JAMA"},{"key":"1254_CR3","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","volume":"100","author":"JL Spivak","year":"2002","unstructured":"Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272\u201390.","journal-title":"Blood"},{"key":"1254_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1254_CR5","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.3324\/haematol.2018.213108","volume":"104","author":"RT Silver","year":"2019","unstructured":"Silver RT, Krichevsky S. Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values. Haematologica . 2019;104:2200\u20135.","journal-title":"Haematologica"},{"key":"1254_CR6","first-page":"339","volume":"12","author":"NI Berlin","year":"1975","unstructured":"Berlin NI. Diagnosis and classification of the polycythemias. Semin. Hematol.1975;12:339\u201351.","journal-title":"Semin. Hematol."},{"key":"1254_CR7","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544\u201351.","journal-title":"Blood"},{"key":"1254_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","volume":"1","author":"H Yoshihara","year":"2007","unstructured":"Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, et al. Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1:685\u201397.","journal-title":"Cell Stem Cell"},{"key":"1254_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature12495","volume":"502","author":"A Sanjuan-Pla","year":"2013","unstructured":"Sanjuan-Pla A, Macaulay IC, Jensen CT, Woll PS, Luis TC, Mead A, et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature 2013;502:232\u20136.","journal-title":"Nature"},{"key":"1254_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.cell.2013.08.007","volume":"154","author":"R Yamamoto","year":"2013","unstructured":"Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, Rudolph KL, et al. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell 2013;154:1112\u201326.","journal-title":"Cell"},{"key":"1254_CR11","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","volume":"108","author":"AR Moliterno","year":"2006","unstructured":"Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006;108:3913\u20135.","journal-title":"Blood"},{"key":"1254_CR12","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 2017;31:2726\u201331.","journal-title":"Leukemia"},{"key":"1254_CR13","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","volume":"4","author":"T Karantanos","year":"2020","unstructured":"Karantanos T, Chaturvedi S, Braunstein EM, Spivak J, Resar L, Karanika S, et al. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020;4:2567\u201376.","journal-title":"Blood Adv"},{"key":"1254_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","volume":"30","author":"R Kralovics","year":"2002","unstructured":"Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol.2002;30:229\u201336.","journal-title":"Exp. Hematol."},{"key":"1254_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet.2009;41:446\u20139.","journal-title":"Nat. Genet."},{"key":"1254_CR16","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","volume":"25","author":"E Rumi","year":"2007","unstructured":"Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L. et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J. Clin. Oncol.2007;25:5630\u20135.","journal-title":"J. Clin. Oncol."},{"key":"1254_CR17","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","volume":"99","author":"C Nielsen","year":"2014","unstructured":"Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica 2014;99:1448\u201355.","journal-title":"Haematologica"},{"key":"1254_CR18","doi-asserted-by":"publisher","first-page":"E84","DOI":"10.1002\/ajh.25014","volume":"93","author":"O Mansier","year":"2018","unstructured":"Mansier O, Luque PD, Ianotto JC, Le BY, Chauveau A, Boyer F. et al. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am. J. Hematol.2018;93:E84\u2013E6.","journal-title":"Am. J. Hematol."},{"key":"1254_CR19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","volume":"36","author":"AR Moliterno","year":"2008","unstructured":"Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp. Hematol.2008;36:1480\u20136.","journal-title":"Exp. Hematol."},{"key":"1254_CR20","doi-asserted-by":"crossref","unstructured":"Mora B, Siracusa C, Rumi E, Maffioli M, Casetti IC, Barraco D.et al. Platelet count predicts driver mutations\u2019 co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis. Leukemia. 2020.","DOI":"10.1038\/s41375-020-01053-9"},{"key":"1254_CR21","doi-asserted-by":"publisher","first-page":"e0232801","DOI":"10.1371\/journal.pone.0232801","volume":"15","author":"JL Spivak","year":"2020","unstructured":"Spivak JL, Merchant A, Williams DM, Rogers O, Zhao W, Duffield A. et al. Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS ONE. 2020;15:e0232801.","journal-title":"PLoS ONE"},{"key":"1254_CR22","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.3324\/haematol.2018.215582","volume":"105","author":"N Maslah","year":"2020","unstructured":"Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, et al. Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses. Haematologica 2020;105:e95\u2013e7.","journal-title":"Haematologica"},{"key":"1254_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1403141","volume":"371","author":"JL Spivak","year":"2014","unstructured":"Spivak JL, Considine M, Williams DM, Talbot CC,Jr, Rogers O, Moliterno AR. et al. Two clinical phenotypes in polycythemia vera. N. Engl. J. Med.2014;371:808\u201317.","journal-title":"N. Engl. J. Med."},{"key":"1254_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2008.357","volume":"23","author":"L Catani","year":"2009","unstructured":"Catani L, Zini R, Sollazzo D, Ottaviani E, Vannucchi AM, Ferrari S, et al. Molecular profile of CD34+stem\/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia 2009;23:997\u20131000.","journal-title":"Leukemia"},{"key":"1254_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","volume":"25","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E, et al. Molecular profiling of CD34+cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms\u2019 tumor gene 1 (WT1). Stem Cells. 2007;25:165\u201373.","journal-title":"Stem Cells"},{"key":"1254_CR26","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","volume":"119","author":"JM Gerber","year":"2012","unstructured":"Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 2012;119:3571\u20137.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01254-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01254-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01254-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:42:11Z","timestamp":1684618931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01254-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1254"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01254-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}